BERLIN, Germany I November 3, 2014 I The LEISHDNAVAX consortium, with the biotechnology company MOLOGEN AG as a key partner, presented preclinical data of the leishmaniasis vaccine (MGN1331) in a poster at the International Meeting on Emerging Diseases and Surveillance (IMED) in Vienna. Data on the immunogenicity and prophylactic efficacy of the DNA-based leishmaniasis vaccine was shown.
Leishmaniasis is a neglected tropical disease that severely affects large populations worldwide. A vaccine is needed to prevent, control and eliminate leishmaniasis in endemic regions. The abstract and more information on LEISHDNAVAX (MGN1331) can be found on: http://imed.isid.org/.
Abstract details:
Abstract number: 22.149
Title: “Multiantigen T cell epitope-enriched leishmaniasis vaccine”
About leishmaniasis
Leishmaniasis is a cluster of diseases caused by different species of Leishmania parasites with diverse clinical manifestations, most of them difficult to treat or even fatal if untreated. On five continents, leishmaniasis occurs in tropical and subtropical regions and has been classified by the WHO as a very important Neglected Tropical Disease. According to WHO (2010), approximately 350 million people are at risk of contracting leishmaniasis with an estimated number of approximately two million new cases per year. Recent epidemiological evaluations by WHO resulted in an estimate of around 40,000 deaths caused by visceral leishmaniasis annually. Among parasitic diseases, this rate is surpassed only by malaria. Moreover, each year approximately 1.2 million people develop cutaneous leishmaniasis.
About MGN1331
The DNA vaccine MGN1331 consists of a combination of MIDGE® vectors encoding different Leishmania antigens. In animal models, promising efficacy and a very good safety profile of MGN1331 has been shown.In the field of biotechnology, transport vehicles for conveying nucleic acids (mostly DNA) are called vectors. The MIDGE® technology developed by MOLOGEN (MIDGE® stands for Minimalistic Immunologically Defined Gene Expression) is also termed a DNA vector. However, unlike other DNA vectors (plasmids, viruses), the MIDGE® vector contains only the information necessary for the actual effect. Its minimalistic design ensures avoidance of undesirable components often found in conventional vectors.MIDGE® vectors form the basis for a broad spectrum of modern, DNA-based applications. These vectors are designed with various characteristics that are partly individualized and are exceptionally well-suited for both gene therapy for cancer and DNA-based vaccination against infectious diseases.
Members of the LEISHDNAVAX consortium:
- London School of Hygiene & Tropical Medicine (LSHTM)
- Charité – Universitätsmedizin Berlin (Charite)
- Indian Institute of Chemical Biology (IICB), Kolkata
- Institut Pasteur de Tunis (IPT)
- Hebrew University of Jerusalem (HUJI)
- Rajendra Memorial Research Institute of Medical Sciences (RMRI-MS)
- Drugs for Neglected Diseases Initiative (DNDi)
- MOLOGEN AG
About MOLOGEN AG
MOLOGEN AG is a biotechnology company specialized in the research and clinical development of cancer immune therapies and DNA vaccines against infectious diseases. The cancer immune therapy MGN1703 is the company’s lead product and best-in-class TLR-9 agonist. It is currently developed for first-line maintenance treatment of colorectal cancer (pivotal randomized trial) and lung cancer (randomized controlled trial). A second clinical-stage product is MGN1601, a therapeutic vaccination for the treatment of renal cancer. A phase I/II clinical study has already been completed successfully. With unique, patented technologies and innovative products, MOLOGEN is pioneering immune therapies. MOLOGEN AG is a publicly listed company, headquartered in Berlin. The shares (ISIN DE0006637200) are listed in the Prime Standard of the German Stock Exchange.
SOURCE: Mologen
Post Views: 711
BERLIN, Germany I November 3, 2014 I The LEISHDNAVAX consortium, with the biotechnology company MOLOGEN AG as a key partner, presented preclinical data of the leishmaniasis vaccine (MGN1331) in a poster at the International Meeting on Emerging Diseases and Surveillance (IMED) in Vienna. Data on the immunogenicity and prophylactic efficacy of the DNA-based leishmaniasis vaccine was shown.
Leishmaniasis is a neglected tropical disease that severely affects large populations worldwide. A vaccine is needed to prevent, control and eliminate leishmaniasis in endemic regions. The abstract and more information on LEISHDNAVAX (MGN1331) can be found on: http://imed.isid.org/.
Abstract details:
Abstract number: 22.149
Title: “Multiantigen T cell epitope-enriched leishmaniasis vaccine”
About leishmaniasis
Leishmaniasis is a cluster of diseases caused by different species of Leishmania parasites with diverse clinical manifestations, most of them difficult to treat or even fatal if untreated. On five continents, leishmaniasis occurs in tropical and subtropical regions and has been classified by the WHO as a very important Neglected Tropical Disease. According to WHO (2010), approximately 350 million people are at risk of contracting leishmaniasis with an estimated number of approximately two million new cases per year. Recent epidemiological evaluations by WHO resulted in an estimate of around 40,000 deaths caused by visceral leishmaniasis annually. Among parasitic diseases, this rate is surpassed only by malaria. Moreover, each year approximately 1.2 million people develop cutaneous leishmaniasis.
About MGN1331
The DNA vaccine MGN1331 consists of a combination of MIDGE® vectors encoding different Leishmania antigens. In animal models, promising efficacy and a very good safety profile of MGN1331 has been shown.In the field of biotechnology, transport vehicles for conveying nucleic acids (mostly DNA) are called vectors. The MIDGE® technology developed by MOLOGEN (MIDGE® stands for Minimalistic Immunologically Defined Gene Expression) is also termed a DNA vector. However, unlike other DNA vectors (plasmids, viruses), the MIDGE® vector contains only the information necessary for the actual effect. Its minimalistic design ensures avoidance of undesirable components often found in conventional vectors.MIDGE® vectors form the basis for a broad spectrum of modern, DNA-based applications. These vectors are designed with various characteristics that are partly individualized and are exceptionally well-suited for both gene therapy for cancer and DNA-based vaccination against infectious diseases.
Members of the LEISHDNAVAX consortium:
- London School of Hygiene & Tropical Medicine (LSHTM)
- Charité – Universitätsmedizin Berlin (Charite)
- Indian Institute of Chemical Biology (IICB), Kolkata
- Institut Pasteur de Tunis (IPT)
- Hebrew University of Jerusalem (HUJI)
- Rajendra Memorial Research Institute of Medical Sciences (RMRI-MS)
- Drugs for Neglected Diseases Initiative (DNDi)
- MOLOGEN AG
About MOLOGEN AG
MOLOGEN AG is a biotechnology company specialized in the research and clinical development of cancer immune therapies and DNA vaccines against infectious diseases. The cancer immune therapy MGN1703 is the company’s lead product and best-in-class TLR-9 agonist. It is currently developed for first-line maintenance treatment of colorectal cancer (pivotal randomized trial) and lung cancer (randomized controlled trial). A second clinical-stage product is MGN1601, a therapeutic vaccination for the treatment of renal cancer. A phase I/II clinical study has already been completed successfully. With unique, patented technologies and innovative products, MOLOGEN is pioneering immune therapies. MOLOGEN AG is a publicly listed company, headquartered in Berlin. The shares (ISIN DE0006637200) are listed in the Prime Standard of the German Stock Exchange.
SOURCE: Mologen
Post Views: 711
